SKYSCRAPER-01 study of tiragolumab + Tecentriq in PD-L1-high metastatic NSCLC missed co-primary PFS endpoint in interim results

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

In Brief

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.

March 20, 2026

Vol.52 No.11

Funding Opportunities

SITC seeks applications for two fellowships

Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Drugs & Targets

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.

March 20, 2026

Vol.52 No.11

Guest Editorial

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

March 13, 2026

Vol.52 No.10

By Karen E. Knudsen

SKYSCRAPER-01 study of tiragolumab + Tecentriq in PD-L1-high metastatic NSCLC missed co-primary PFS endpoint in interim results

YOU MAY BE INTERESTED IN

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

SITC seeks applications for two fellowships

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

START, Trialing collaborate to expand access to oncology clinical trials across Europe

As more people are surviving cancer, we must continue funding bold science

Renew today!

Subscriber content

Never miss an issue!

Login